About Us
Armaceutica, Inc. was founded in 2019 as a Texas C corporation focused on developing a drug to treat various types of cancer. Our team is comprised of experts in the fields of cancer research, drug development, and the patenting of pharmaceutical products.
Our Team
ERNEST T. ARMSTRONG, MBA
CHIEF EXECUTIVE OFFICER
Mr. Armstrong’s undergraduate education was at Humboldt State University, California. BA degree in Business and biology studies. He attended graduate school at University of California at Santa Barbara (UCSB), statistics, management program in Japan. He gained his MBA from San Francisco State University. Mr. Armstrong has worked in the pharmaceuticals industry since the 1990s. He has presented and/or negotiated with some 200 pharmaceutical companies, many for licensing or asset purchase opportunities. He has had responsibility for large, late-stage drug development programs with budgets of over $10 million. He has worked with the FDA and written documents on approval and regulatory matters and has invented and authored several medical patents. He speaks six languages. He is the inventor and developer of vitamin D promoting sunscreens.
RENATO J. AGUILERA, PHD
CHIEF SCIENTIFIC OFFICER, PROFESSOR OF BIOLOGY
Full Professor of Biology at the University of Texas at El Paso (UTEP) where he conducts cancer biology and immunology research. Dr Aguilera’s work on pyronaridine as a treatment for cancer has been groundbreaking. He was a tenured professor at the University of California at Los Angeles (UCLA) for 14 years. He holds BS and MS degrees in biology from the University of Texas at El Paso (UTEP). He gained a PhD in immunology from the University of California, Berkeley. Dr. Aguilera is the author or co-author of 100 scientific papers, generally on cancer and immunology, including on pyronaridine. He is the inventor of three biomedical patents. He was inducted into the California Academy of Sciences in 2024. Wikipedia page:
https://en.wikipedia.org/wiki/Renato_Aguilera
MANUEL L. PENICHET, MD, PHD
MEDICAL ADVISOR, PROFESSOR OF MEDICINE
He holds an M.D. and a doctorate in biochemistry from the Havana Advanced Institute of Medical Sciences in Cuba. Since 1996, he has worked at the University of California, Los Angeles (UCLA) in the fields of immunology, immunotherapy, antibody engineering, and nanotechnology, focusing on cancer and infectious diseases. He is a Professor in the Division of Surgical Oncology at UCLA Department of Surgery. Dr. Penichet is author or co-author of more than 100 publications including original papers, reviews, book chapters, and a book. He has worked extensively as a consultant or reviewer of research projects for biotech and state and federal agencies in the United States and abroad. He is a member of the Jonsson Comprehensive Cancer Center.
MICHAEL F. HOLICK, PHD, MD
MEDICAL ADVISOR, PROFESSOR OF MEDICINE
Dr. Holick received his Ph.D. in biochemistry and his M.D. degree from the University of Wisconsin. He works as Professor of Medicine, Physiology and Biophysics at the Boston University Chobanian and Avedisian School of Medicine. He has focused on dermatology and vitamin D. He has served as the chair for NASA’s Research Committee on Human Health and Performance for the bone health of astronauts. He is the editor-in-chief for the Journal of Clinical Laboratory and has served as an associate editor for the journal Dermato-Endocrinology. He has published over 600 manuscripts in well-respected peer-reviewed journals and more than 200 reviews and book chapters. There are more than 150,000 citations for his work. He is a prostate cancer survivor and marathon runner.
MARTHA E. STEWART, MD
MEDICAL ADVISOR, DERMATOLOGIST
Dr. Stewart is board-certified in Dermatology and has been in private practice for over 20 years. She earned her medical degree from Tulane University School of Medicine in New Orleans, Louisiana and completed her internship in internal medicine and residency in dermatology at Louisiana State University Medical Center. Dr. Stewart received the Louisiana Dermatological Society’s Peterkin award for outstanding resident research project. She has provided informational seminars on skin cancer awareness. She is actively involved in various clinical research trials. She is a member of the American Society for Dermatologic Surgery and a Fellow, American Academy of Dermatology. She has administered pyronaridine as a cancer treatment.
CATHERINE R. POSEY-SARINANA, CCRC
HEAD OF CLINICAL RESEARCH
Catherine Posey-Sarinana has been conducting clinical research since the 1990s. She is a Certified Clinical Research Coordinator (CCRC) through the Association of Clinical Research Professionals (ACRP). Her clinical research has focused on immunology. She has co-authored Armaceutica’s clinical research protocols on leukemia.
ZORAN DJORDJEVICH, DVM
ADVISOR FOR VETERINARY CANCERS
Dr. Djordjevich earned his veterinary medical degree from the University of Belgrade, Serbia in 1990. He trained at the Royal Veterinary College in London, England and the University of California, Davis. Since joining Mohnacky Animal Hospital in Carlsbad, California in 1998, he has supported animal rescue groups and other animal welfare organizations. His interests outside of work include soccer, tennis, and table tennis. He is a member of the American Veterinary Medical Association (AVMA). He regularly treats domestic animals with cancer. He has successfully treated dogs with a variety of cancers using pyronaridine.
NAOMI PEARCE, JD
PATENT ATTORNEY
Ms. Pearce is CEO of Pearce IP, is a market leading, strategic, commercially astute, patent lawyer with over 25 years’ experience. She has a background in molecular biology and biochemistry. Her degrees include a Masters of Industrial Property, Bachelor of Laws, and a Bachelor of Science in Molecular Genetics. Among other awards, Ms. Pearce is ranked in IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents. Underpinning her legal work is a deep understanding of life sciences industries, resulting from first-hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm. Her industry focus is life sciences, with a particular focus on health, pharmaceuticals/ biopharmaceuticals. With her guidance, Armaceutica has been able to secure its cancer-drug patents in many countries.
BELINDA HARTMANN, PHD, JD
PATENT ATTORNEY
Dr. Belinda Hartmann is a patent attorney. She has a background in biochemistry, pharmaceuticals, immunology, and biotechnology. She completed her Masters in Intellectual Property at the University of Technology Sydney, Australia. Her other qualifications include: Bachelor of Biotechnology, Griffith University, Bachelor of Science with Honors (Biochemistry), Griffith University, Graduate Certificate in Research Commercialisation, University of Queensland Doctor of Philosophy (Biotechnology and Bioengineering), University of Queensland, and Registered Patent Attorney. She co-authored Armaceutica’s cancer drug patents.
CARLOS TEJEDA
VP OF INVESTOR RELATIONS
Mr. Tejeda attended California State University at Los Angeles and the American Institute where he earned his degree in Business Finance. He was Director of Operations for the Coca Cola Company, Ontario, California. He was CFO and a Board Member of the pharmaceutical company Cobalis Corp in Irvine, California. He has over 20 years of experience in the pharmaceuticals industry.
LYNDON E. MANSFIELD, MD, CPI
DEVELOPED OUR DRUG AND CLINICAL STUDY PROTOCOL
Dr. Lyndon Mansfield was board certified in Allergy and Clinical Immunology, and in Diagnostic Laboratory Immunology/Clinical Lab Immunology. He was a Clinical Professor of Pediatrics. He was a Certified Principal Investigator, conducted dozens of clinical studies, and worked with pharmaceutical companies on clinical study design, protocol development and as a representative for regulatory matters to the FDA. He authored or co-authored over 90 medical manuscripts and over 104 scientific research presentations. Dr. Mansfield was involved in clinical research for over 30 years. He was trained in medicine at Thomas Jefferson Medical University, UC Irvine and UCLA. We remember our friend and colleague as Dr. Mansfield sadly passed away after completing Armaceutica’s leukemia clinical study protocol and contributing substantially to our drug’s development.
